Clinical Trial Update: Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating exeporfinium chloride gel (XF-73) for reducing Staphylococcus aureus-related infections in surgical patients; study completed with post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcal Infections
• Surgical Site Infection

Drugs mentioned

• Exeporfinium chloride gel (exeporfinium chloride)

Snippet

Sponsor: Destiny Pharma Plc | Conditions: Staphylococcal Infections, Surgical Site Infection | Phase 2 | Status: COMPLETED | Results posted: 2022-06-01